Cover Image
市場調查報告書

Dicerna Pharmaceuticals, Inc.:產品平台分析

Dicerna Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 308421
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Dicerna Pharmaceuticals, Inc.:產品平台分析 Dicerna Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 39 Pages
簡介

Dicerna Pharmaceuticals, Inc.正在開發罕見遺傳性疾病治療藥的生物製藥公司。該公司由獨家RNA介面製造產品,並擁有以RNAi為標的的各種產品。

本報告提供Dicerna Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Dicerna Pharmaceuticals, Inc.的基本資料

  • Dicerna Pharmaceuticals, Inc.概要
  • 主要資訊
  • 企業資料

Dicerna Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Dicerna Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Dicerna Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Dicerna Pharmaceuticals, Inc.:藥物簡介

  • DCRM-1711
  • Antisense RNAi Oligonucleotide to Inhibit BCAT for Solid tumors
  • Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology
  • DCRPH-1
  • Antisense RNAi Oligonucleotide 2 for Rare Liver Diseases
  • Antisense RNAi Oligonucleotide for Liver Fibrosis
  • Antisense RNAi Oligonucleotides for Liver Diseases
  • RNAi Oligonucleotide for Alpha- Antitrypsin Deficiency and Liver Disease
  • RNAi Oligonucleotide for Clotting Disorder
  • RNAi Oligonucleotide for Rare Liver Diseases

Dicerna Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Dicerna Pharmaceuticals, Inc.:最近的開發平台趨勢

Dicerna Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07493CDB

Summary

Global Markets Direct's, 'Dicerna Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Dicerna Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dicerna Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Dicerna Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Dicerna Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Dicerna Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Dicerna Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Dicerna Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Dicerna Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Dicerna Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dicerna Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Dicerna Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Dicerna Pharmaceuticals, Inc. Snapshot
    • Dicerna Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Dicerna Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Dicerna Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Dicerna Pharmaceuticals, Inc. - Pipeline Products Glance
    • Dicerna Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Dicerna Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Dicerna Pharmaceuticals, Inc. - Drug Profiles
    • DCRM-1711
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit BCAT for Solid tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DCRPH-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide 2 for Rare Liver Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide for Liver Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides for Liver Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Alpha- Antitrypsin Deficiency and Liver Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Clotting Disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Rare Liver Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Dicerna Pharmaceuticals, Inc. - Pipeline Analysis
    • Dicerna Pharmaceuticals, Inc. - Pipeline Products by Target
    • Dicerna Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Dicerna Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Dicerna Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Dicerna Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Dicerna Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Dicerna Pharmaceuticals, Inc., Key Information
  • Dicerna Pharmaceuticals, Inc., Key Facts
  • Dicerna Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Dicerna Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Dicerna Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Dicerna Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Dicerna Pharmaceuticals, Inc. - Phase I, 2015
  • Dicerna Pharmaceuticals, Inc. - Preclinical, 2015
  • Dicerna Pharmaceuticals, Inc. - Discovery, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Dicerna Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Dicerna Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Dicerna Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Dicerna Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top